latest update:
[TrialBase DB]

trial summary · NCT07674277

Virtual Reality for SCD VOC

Randomized EvaLuation of ImmErsive Virtual Experiences in Sickle Cell Disease (RELIEVE-SCD)

Trial record from the TrialBase DB dataset, status RECRUITING, condition Sickle Cell Disease, sponsored by University of Maryland, Baltimore. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07674277phase —enrollment 50start 2026-11-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This randomized pilot study will evaluate the feasibility, tolerability, and preliminary analgesic effect of headset-based virtual reality (VR) interventions for adults with sickle cell disease (SCD) experiencing vaso-occlusive crisis (VOC) treated in an infusion center. Up to 50 participants will be enrolled, provide informed consent, and undergo randomization during routine outpatient sickle cell clinic visits when they are clinically stable and not experiencing an acute VOC. Using a randomized, two-period crossover design, each participant will be assigned to receive two of three headset-based interventions during separate qualifying infusion center visits for vaso-occlusive pain occurring within six months of enrollment: sham 2D headset control, passive immersive 3D VR, or active immersive interactive 3D VR. Each intervention will be delivered during a 45-minute session as an adjunct to usual clinical care. The primary outcome is pain burden during the first 60 minutes after intervention start, measured as the area under the curve of 0-10 numeric rating scale pain scores. Secondary outcomes include feasibility of intervention delivery, headset tolerability, pain at 120 minutes, opioid consumption, and participant-reported immersion and acceptability. Findings will inform the design of future trials evaluating VR as an adjunctive treatment for acute vaso-occlusive pain.

Source record: https://clinicaltrials.gov/study/NCT07674277

Facts

registry idNCT07674277
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasenot reported
study typeINTERVENTIONAL
lead conditionSickle Cell Disease
sponsorUniversity of Maryland, Baltimore
sponsor classOTHER
enrollment50
start date2026-11-01
primary completion2027-12
completion2028-03
results postednot reported

Conditions

  • Sickle Cell Disease

Interventions

  • Sham 2D Headset Control
  • Passive Immersive 3D Virtual Reality
  • Active Immersive Interactive 3D Virtual Reality

Countries

  • United States

Intervention types: DEVICE

Work with this record